Innealta Capital’s Arcus Biosciences RCUS Stock Holding History

Innealta Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,338	Closed	-$66.1K	–	1324
2024 Q2	$66.1K	Buy	+4,338	New	+$70K	0.02%	296

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Innealta Capital's RCUS Position: Q3 2024 in Review

Innealta Capital sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 4,338 shares — an estimated $66.1K sold.

Innealta Capital first reported a position in RCUS in Q2 2024 and held it in 1 quarter. The position peaked at $66.1K in Q2 2024. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

Innealta Capital reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 4,338 Arcus Biosciences shares in Q3 2024, an estimated $66.1K.
Innealta Capital first reported a position in Arcus Biosciences in Q2 2024 and held it in 1 quarter.
Innealta Capital's Arcus Biosciences position peaked at $66.1K in Q2 2024.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.